bioMerieux expands diagnostics sales with Organon deal
This article was originally published in Clinica
Executive Summary
bioMerieux is set to become the seventh largest in vitro diagnostics manufacturer in the world when it completes the acquisition of the diagnostics business of Organon Teknika. bioMerieux made an offer to Organon's parent, Akzo Nobel, for the business last week, pricing the division at around $320 million.